Pharmicell Co., Ltd.

KSC:005690.KS

$7120 KRW

$560 (8.54%)

Volume
7.72M
Average Volume
722.47K
Market Capitalization
$427.23B
P/E Ratio
124.23
Dividend Yield
0.00%
Price Target
$
Year High
$8870.00
Year Low
$4300.00
Payout Ratio
$0.00
Current Ratio
$9.01

Industry, Sector & symbol

Stock Exchange KSE
CEO Mr. Hyun-Soo Kim
Industry Biotechnology
Sector Healthcare
Current Symbol 005690.KS
CUSIP None
CIK None
Web https://www.pharmicell.com
Phone 82 2 3496 0114
Currency KRW
Employees 136
Country KR

Liquidity

Debt-to-Equity Ratio 0.00
Payout Ratio 0.00
Current Ratio 9.01
Quick Ratio 4.44
Cash Ratio 2.28

Sales & Book Value

Annual Sales $56.23B
Price / Sales 7.55
Cash Flow -30.90
Price / Cash Flow -232.37
Price / Book 5.13

Price Target and Rating

Average Stock Price Forecast $
High Stock Price Forecast $
Low Stock Price Forecast $
Forecast Upside/Downside %
Consensus Rating Sell
Rating Score(0-5) 2
Research Coverage 0 Analysts

Profitability

EPS (Most Recent Fiscal Year) $59.63
Trailing P/E Ratio 124.23
PEG Ratio -13.35
P/E Growth -13.35
Net Income $3.58B
Net Margin 6.03%
Pretax Margin 8.07%
Return on Equity 4.21%
Return on Assets 3.72%

Financials Score

AltmanZ Score 27.07
Piotroski Score 8.00
Working Capital 35.47B
Total Assets 91.72B
Ebit 4.58B
Market Cap 393.63B
Total Liabilities 9.16B

Poll Results

About Pharmicell Co., Ltd. (KSC:005690.KS) Stock

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to enhance the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; and Cellgram_DC, a cancer drug, as well as Hearticellgram_AM, a cardiac disease drug. It also develops and produces intermediates of raw material medicines, such as nucleosides, mPEGs, HDP-tosylate, and vincelactam; and low dielectric constant material, ... eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company operates Twelve, a stem cell bank; develops and sells stem cell culture media cosmetics. Pharmicell Co., Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.

Frequently Asked Questions

What is the current Pharmicell Co., Ltd. (005690.KS) stock price?

Pharmicell Co., Ltd.(KSC:005690.KS) stock price is $7120 in the last trading session. During the trading session, 005690.KS stock reached the peak price of $8870.0 while $4300.0 was the lowest point it dropped to. The percentage change in 005690.KS stock occurred in the recent session was 8.54% while the dollar amount for the price change in 005690.KS stock was $560.

005690.KS's industry and sector of operation?

The KSC listed 005690.KS is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of 005690.KS?

Mr. Hyun-Soo Kim | Chief Executive Officer and Inside Director
|
|
|
|

How many employees does 005690.KS have?

Number of 005690.KS employees currently stands at 136. 005690.KS operates from Ssangbong Building, Seoul, None None, KR.

Link for 005690.KS official website?

Official Website of 005690.KS is: https://www.pharmicell.com

How do I contact 005690.KS?

005690.KS could be contacted at phone #82 2 3496 0114 and can also be accessed through its website. 005690.KS operates from Ssangbong Building, Seoul, None None, KR.

How many shares of 005690.KS are traded daily?

The average number of 005690.KS shares traded daily for last 3 months was 722.47K.

What is the market cap of 005690.KS currently?

The market value of 005690.KS currently stands at $427.23B with its latest stock price at $7120